Hepatitis B virus antisense oligonucleotide - F-star Therapeutics
Alternative Names: Antisense HBx protein oligonucleotide; Antisense oligonucleotide HBx protein; HBx gene antagonist; SB-11527; SB-527Latest Information Update: 28 Jun 2023
At a glance
- Originator Spring Bank Pharmaceuticals
- Developer F-star Therapeutics
- Class Antisense oligonucleotides; Antivirals
- Mechanism of Action Hepatitis B virus replication inhibitors; Hepatitis B virus X protein inhibitors; RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Hepatitis B
Most Recent Events
- 28 Jun 2023 No recent reports of development identified for preclinical development in Hepatitis-B in USA (Parenteral)
- 09 Mar 2023 F-star Therapeutics has been acquired by invoX Pharma
- 20 Nov 2020 Spring Bank Pharmaceuticals has merged with F-star to form F-star Therapeutics